

THERAPEUTIC AREA	PRODUCT	INDICATION	SAMPLES	TECHNICAL PACKAGE	VALIDATION BATCH	DMF
Antiasthmatics, COPD and respiratory diseases	Abediterol	Asthma and COPD			Early R&D	
	Acclidinium bromide	COPD	√	Q1 2019	Q1 2019	2019
	Batefenterol	COPD			Early R&D	
	Indacaterol maleate^P	Asthma and COPD	√	√	√	2019
	Olodaterol^P	COPD	Q1 2019	Q1 2019	Q1 2019	
	Revefenacin	COPD			Early R&D	
	Roflumilast	COPD with chronic bronchitis	√	Q1 2019		
	Tiotropium Bromide	COPD	√	√	√	2019
	Umeclidinium bromide	COPD	√	√	Q1 2019	2019
	Vilanterol	Asthma and COPD	Q4 2018	Q4 2018	Q1 2019	2019
Antiemetics	Aprepitant	Emesis	√	√	√	2019
Antihypertensive	Clevidipine^P	Hypertension	√	√		
Antihyperparathyroidism	Cinacalcet	Hyperparathyroidism/Hypercalcaemia	√	√	√	
Antiparkinson	Benserazide	Parkinson's disease				2020
	Tetrabenazine	Huntington's disease chorea and Tardive dyskinesia	√	√	√	2019
	(+) Tetrabenazine	Huntington's disease chorea and Tardive dyskinesia	√	√		
Antipsychotics	Brexipiprazole	Schizophrenia and major depressive disorders		Q4 2018	Q1 2019	
	Olanzapine pamoate (sterile)	Schizophrenia, psychosis	√	√		2019
	Paliperidone	Schizophrenia, bipolar mania				2019
	Paliperidone palmitate	Schizophrenia, bipolar mania				2019
	Pipamperone	Schizophrenia				2019
Antithrombotics	Apixaban^P	Venous thromboembolism	√	√	√	
	Prasugrel hydrochloride	Prophylaxis and therapy of thrombosis	√	√		
	Rivaroxaban^P	Thrombosis, Stroke	√	√	√	DMF
Other disorders	Tolvaptan	Hiponatremia	√	√		
Urologics	Imidafenacin^P	Urinary incontinence	√	√		

CEP = Products with Certificate of Suitability / P = Patent applications/granted patents owned by Neuraxpharm

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular, these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2014, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.